Geoffrey Shouse, D.O., Ph.D.
Hematologist-Oncologist
4.9 (213 RATINGS)
Clinical Expertise
- Lymphoma
- Hematology and Hematopoietic Cell Transplantation
- Clinical Cellular Immunotherapy
Research Area
- Cellular Therapy
- Molecular Targeted Therapy
- Immunotherapy for Lymphoma
- Assessing and Improving Toxicity in Patients with Lymphoma Undergoing Cellular Therapy
Other Languages Spoken
Spanish
Academic Appointments
- Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Lymphoma
“Dr. Shouse is a very special doctor. He listened attentively to my concerns, and he treated me with kindness and patience.”
— Patient”
— Patient”
Geoffrey Shouse, D.O., Ph.D.'s fascination with molecular biology led him to hematology and oncology as a career. He earned a Ph.D. in cell, molecular and developmental biology at the University of California Riverside, and went on to study medicine at Western University of Health Sciences in Pomona, California. He continued his residency and fellowship training at Loma Linda University Medical Center, with additional fellowship training at City of Hope in stem cell transplant and cellular therapy.
Dr. Shouse focuses his research on eliminating the barriers of lymphoma cure. He is the primary investigator on numerous clinical trials including utilizing cutting edge treatments to more effectively treat lymphoma. These include cell therapies, molecular targeted therapies and immunotherapy. In addition, he leads studies designed to improve outcomes in older adults facing the sometimes daunting toxicities of lymphoma therapy. Finally, he designs and implements clinical trials focused on enhanced access and recruitment of underrepresented minorities.
He cares deeply about his patients and has become an essential member of City of Hope's team.
Location
Duarte Cancer Center
1500 East Duarte Road
Duarte, CA 91010
Duarte, CA 91010
Education & Experience
2007-2012, Ph.D., Osteopathic Medicine, Western University of Health Sciences, Pomona, CA
2003-2009, Ph.D., Cell, Molecular, and Developmental Biology, University of California Riverside, Riverside, CA
1998-2002, B.S., Biology, University of California Riverside, Riverside, CA
2019, Fellowship in Bone Marrow Transplantation, City of Hope, Duarte, CA
2015-2018, Fellowship in Hematology and Medical Oncology, Loma Linda University Medical Center, Loma Linda, CA
2006-2012, Postdoctoral Fellow, Cell, Molecular and Developmental
Biology, Department of Biochemistry, University of California Riverside, Riverside, CA
2012-2015, Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA
2020-present, Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2018, Assistant Professor of Medicine, Division of Hematology and Oncology, Loma Linda University Medical Center, Loma Linda, CA
Awards & Memberships
Awards
2024 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI 2024 PMBCL Accelerator Fund City of Hope, Department of HCT Duarte, CA 2024 Schwartz Accelerator Fund City of Hope, Department of HCT Duarte, CA 2023 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI 2024 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI 2024 PMBCL Accelerator Fund City of Hope, Department of HCT Duarte, CA 2024 Schwartz Accelerator Fund City of Hope, Department of HCT Duarte, CA 2023 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI 2024 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI 2024 PMBCL Accelerator Fund City of Hope, Department of HCT Duarte, CA 2024 Schwartz Accelerator Fund City of Hope, Department of HCT Duarte, CA 2023 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI 2024 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI 2024 PMBCL Accelerator Fund City of Hope, Department of HCT Duarte, CA 2024 Schwartz Accelerator Fund City of Hope, Department of HCT Duarte, CA 2023 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI 2024 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI 2024 PMBCL Accelerator Fund City of Hope, Department of HCT Duarte, CA 2024 Schwartz Accelerator Fund City of Hope, Department of HCT Duarte, CA 2023 Grateful Patient Research Support National Christian Foundation, Michigan Ada, MI - 2024 PMBCL Accelerator Fund, City of Hope, Department of HCT Duarte, CA
- 2024 Schwartz Accelerator Fund, City of Hope, Department of HCT Duarte, CA
- 2023 Grateful Patient Research Support, National Christian Foundation, Michigan Ada, MI
- 2021, Department of Hematology Pilot Project Grant, City of Hope, Department of Hematology & Hematopoietic Cell Transplantation, Duarte, CA
- 2021, CARinG Pilot Grant Award, Cancer and Aging Research Group, Duarte, CA
- 2021, Clinical Research Training Institute, American Society of Hematology, La Jolla, CA
- 2018, First Place Resident and Fellows Poster, Loma Linda University Medical Center, Loma Linda, CA
- 2015, Evidence-Based Medicine Award, Internal Medicine Residency, Loma Linda University Medical Center, Loma Linda, CA
- 2015, Research Award, Internal Medicine Residency, Loma Linda University Medical Center, Loma Linda, CA
- 2015, First Place Resident and Fellows Poster, Annual Postgraduate Conference, Loma Linda University Medical Center, Loma Linda, CA
- 2014, Abstract Achievement Award, ASH Annual Meeting, American Society of Hematology
- 2013-2015, Research Scholar, Internal Medicine Residency, Loma Linda University Medical Center, Loma Linda, CA
- 2013, Third Place Resident Poster Presentation, ACP Regional Meeting, American College of Physicians
- 2013, Best Resident Poster Presentation, SGIM Regional Meeting, Society of General Internal Medicine
- 2011, STARS Research Award, STARS Symposium, Western University of Health Sciences, Pomona, CA
- 2007, Research Award, CMDB Research Symposium, University of California Riverside, Riverside, CA
- 2005, Outstanding Teaching Assistant, Graduate Program in CMDB, University of California Riverside, Riverside, CA
- 2003-2004, Graduate Division Fellowship, Graduate Program in CMDB, University of California Riverside, Riverside, CA
- 1998-2002, Dean's Honor List, Undergraduate Award, University of California Riverside, Riverside, CA
Memberships
- 2019-present, American Society of Transplantation and Cellular Therapy
- 2017-present, American Society of Hematology
- 2015-present American Society of Clinical Oncology
- 2012-present, American College of Physicians
- 2012-present, Society of General Internal Medicine
- 2007-present, American Osteopathic Association
- 2007-present, American Medical Association
Publications
- Melody M, Grover N, Franco S, Romancik J, Cortese M, Moyo TK, Bhansali RS, Ollila T, Kenkre V, Fitzgerald L, Hess B, Matasar M, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Lin A, Danilov A, Roy I, Barta SK, Gordon LI, Stephens D, Cohen JB, Epperla N, Karmali R. Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium. Blood Adv. 2026 Jan 13;10(1):228-232. doi:
- Shouse G, Chen C, Muir A, Popplewell L, Siddiqi T, Zain J, Herrera AF, Danilova O, Roleder C, Wang L, Spurgeon SEF, Kittai AS, Chen L, Xia Z, Davids MS, Danilov AV. Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial. Haematologica. 2026 Jan 1;111(1):259-270. doi: 10.3324/haematol.2024.286945. Epub 2025 Jul 3. PMID: 40605718; PMCID: PMC12775741.
- Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens D, Romancik J, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Matasar M, Herr MM, Davis J, Jesme C, Pelcovits AR, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover N, Karmali R. Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium. Blood Adv. 2026 Feb 10;10(3):725-732. doi: 10.1182/bloodadvances.2025017120. PMID: 41201962; PMCID: PMC12874299.
- Olszewski AJ, Ollila TA, Chihara D, Shouse G, Grover N, Karmali R, Torka P, Thomas C, Geethakumari PR, Barta SK, Bartlett NL, Epperla N. Comparative effectiveness of immunotherapy alone or with chemotherapy as first line treatment for marginal zone lymphoma. Haematologica. 2025 Nov 27. doi: 10.3324/haematol.2025.288946. Epub ahead of print. PMID: 41307133.
- Hodson DJ, Shouse G, Shin HJ, Salar A, Bobillo S, Ribrag V, Macpherson NA, Cordoba R, Kim JS, Guidez S, Herrera AF, Morschhauser F, Colton D, Izuzquiza M, Sambamurthy N, Munugalavadla V, Vicente S, Gorgun G, Chen R, Younes A, Wang ML. Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL). Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-2239. Epub ahead of print. PMID: 41427952.
- Lopedote P, Shouse G, Chen L, Smith DL, Ford J, Herrera AF, Budde LE, Siddiqi T, Kallam A, Phillips TJ, Danilov AV. Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2566316. Epub ahead of print. PMID: 41173230.
- Gao L, Kallam A, Shouse G, Baird JH, Pak S, Qin Y, Song JY, Marcucci G, Ghoda LY, Guillen C, Hyung SJ, Saad OM, Davis H, Dere R, Batlevi CL, Meinert J, Budde LE, Danilov AV, Herrera AF, Kwak LW, Forman SJ, Godfrey JK. Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration. Blood Adv. 2025 Dec 23;9(24):6425-6431. doi: 10.1182/bloodadvances.2025017181. PMID: 41061156; PMCID: PMC12755979.
- Xiao A, Chen L, Pak S, Lee B, Mei M, Budde E, Siddiqi T, Godfrey J, Herrera A, Kallam A, Phillips T, Baird JH, Borogovac A, Kwak L, Rosen ST, Danilov A, Dadwal S, Shouse G, Thiruvengadam SK. Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma. Leuk Lymphoma. 2025 Dec;66(12):2260-2268. doi: 10.1080/10428194.2025.2540442. Epub 2025 Aug 5. PMID: 40765130.
- Altomare NJ, Herr MM, Nair NM, Stephens DM, Cohen JB, Epperla N, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin A, Ma S, Winter JN, Danilov A, Barta SK, Gordon LI, Romancik J, Grover NS, Karmali R; American BiTE and CART Consortium. Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART. Cancers (Basel). 2025 Jul 16;17(14):2358. doi: 10.3390/cancers17142358. PMID: 40723242; PMCID: PMC12294016.
- Miller CR, Huang Y, Allan JN, Bhat SA, Bond D, Brander D, Byrd JC, Chavez J, Chong E, Danilov A, Dowling MR, Dvorak-Kornaus K, Hampel PJ, Ho C, Islam P, Malakhov N, Matasar M, Miller S, Parikh SA, Rabe KG, Rhodes JM, Roeker LE, Rogers KA, Saha A, Skarbnik A, Scott H, Schade J, Shadman M, Shouse G, Sojitra P, Stephens DM, Thompson MC, Thompson PA, Wang Y, Woyach JA, Yano M, Omer Z, Kittai AS. Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era. Am J Hematol. 2025 Sep;100(9):1709-1713. doi: 10.1002/ajh.27760. Epub 2025 Jul 2. PMID: 40600589.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Provider listen carefully to you
5.0
Know important info medical history
5.0
Show respect for what you say
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Spend enough time with you
4.9
Rate provider 0-10
03/16/26
Very excellent!! - Verified patient
02/26/26
Dr. Shouse is very competent and caring. - Verified patient
02/21/26
YES I WILL RECOMMEND.. - Verified patient
02/21/26
I will certainly recommend the Dr as well as COH - Verified patient
02/10/26
All good experience - Verified patient